What is the appropriate management for a female patient who developed confusion after increasing memantine from 5 mg twice daily to 10 mg twice daily?

Immediately reduce memantine back to 5 mg twice daily and monitor for resolution of confusion over the next few days.

The confusion is most likely due to too-rapid dose escalation of memantine, and the appropriate management is to decrease the dose back to the previously tolerated level.

Understanding the Problem

The FDA-approved titration schedule for memantine explicitly states that the minimum recommended interval between dose increases is one week 1. The standard escalation is:

• Start: 5 mg once daily
• Week 1: 10 mg/day (5 mg twice daily)
• Week 2: 15 mg/day
• Week 3: 20 mg/day (10 mg twice daily - target dose)

Your patient jumped from 5 mg BID (10 mg total daily) directly to 10 mg BID (20 mg total daily), which represents a doubling of the dose rather than the recommended 5 mg increment.

Immediate Management Algorithm

Step 1: Reduce the dose immediately

• Decrease memantine back to 5 mg twice daily (the previously tolerated dose)
• Do NOT continue at 10 mg BID

Step 2: Monitor for symptom resolution

• Confusion from memantine is typically mild and transient 2
• Expect improvement within 3-5 days after dose reduction
• If confusion persists beyond one week, consider other causes

Step 3: Rule out other contributing factors

• Check renal function - memantine is renally cleared and accumulates in renal impairment 1
• Review all medications for drug interactions, particularly:
  • Trimethoprim (can cause severe toxicity with memantine) 3
  • Other drugs using organic cation transporter-2 (metformin, imipramine)
• Assess for urinary alkalinization (decreases memantine elimination) 1

Step 4: Resume proper titration when confusion resolves

• Wait at least one week at 5 mg BID
• If patient is stable and confusion has completely resolved, increase to 15 mg/day (5 mg in AM, 10 mg in PM)
• Wait another week before considering increase to target dose of 20 mg/day

Critical Pitfalls to Avoid

Do not assume this is disease progression - Confusion is a recognized adverse effect of memantine 2, and the temporal relationship with dose escalation is highly suggestive of drug-related toxicity.

Do not continue at the current dose hoping tolerance will develop - The FDA label is clear that if a patient misses several days of dosing, you must resume at lower doses and retitrate 1. The same principle applies when a dose is not tolerated.

Check for severe renal impairment - If creatinine clearance is 5-29 mL/min, the maximum recommended dose is only 5 mg twice daily (10 mg total daily) 1. Your patient may have already reached their target dose.

Evidence Context

Confusion is listed as a known adverse effect of memantine in the FDA label 1 and in the literature 2. While generally mild and transient, it can be severe when memantine accumulates due to rapid titration, renal impairment, or drug interactions 3. The clinical trials demonstrating memantine's efficacy used the gradual weekly titration schedule 1, and deviating from this increases the risk of adverse effects without improving efficacy.

The guideline evidence emphasizes that treatment decisions should balance modest benefits against harms 4, and in this case, the harm (acute confusion) clearly outweighs any potential benefit of faster titration.